Where is Purple Biotech headquartered?

PURPLE BIOTECH LTD. is recorded with headquarters in REHOVOT, L3, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Purple Biotech publicly traded?

Yes — Purple Biotech is listed as a public company with ticker PPBT on NYSE in SEC EDGAR-derived records.

What drugs are associated with Purple Biotech?

We link 1 drug profile(s) where Purple Biotech appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Purple Biotech sponsoring?

Purple Biotech is linked to 3 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Purple Biotech as applicant?

3 USPTO PatentsView record(s) name PURPLE BIOTECH LTD. or a normalized variant as applicant.

What therapeutic areas does Purple Biotech target?

Indications and classes aggregated from linked trials and drugs: Head and Neck Cancer, Solid Tumor, Solid Tumor, Adult.

What pipeline phases does Purple Biotech have in our database?

Phase distribution from linked programs: phase 2: 3.

How many US-approved drugs are linked to Purple Biotech?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Where does NovaPharmaNews source data on Purple Biotech?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Purple Biotech data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Purple Biotech data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

PURPLE BIOTECH Pharmaceuticals Company Profile

Name: PURPLE BIOTECH intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: REHOVOT, L3, USA
Founded: 2010
Employees: 12
Programs: 3
Drugs: 4
Patents: 3

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Purple Biotech is a biotech organization headquartered in REHOVOT, L3, USA. It trades on NYSE under ticker PPBT. Primary therapeutic focus areas include Head and Neck Cancer, Solid Tumor, Solid Tumor, Adult. NovaPharmaNews links 3 clinical program(s), 1 drug profile(s), and 3 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (3).

Company snapshot

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219, CM24 and IM1240. *NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancing it as

1 approved product(s) across US/EU regulatory metadata.
3 active pipeline program(s) linked via ClinicalTrials.gov.
3 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for PURPLE BIOTECH. Not investment advice.

Top assets

View drugs (4) View projects (3)

Lead pipeline drugs

amlodipine besylate
approved
dose-escalation
Marketed / approved
escalation
Marketed / approved
nivolumab
approved

Active clinical programs

CM-24 and Nivolumab - Dose Escalation Solid Tumor
Phase 2
NT219 Head and Neck Cancer
Phase 2
NT219 Solid Tumor, Adult
Phase 2

Momentum

Proprietary activity score for PURPLE BIOTECH.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 3 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Corbus Pharmaceuticals

TA overlap score 22.2
Peer + 0 momentum

TScan Therapeutics

TA overlap score 21.8
Peer + 0 momentum

CytomX Therapeutics

TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for PURPLE BIOTECH.

Jun 8, 2026 Clinical update
CM-24 and Nivolumab - Dose Escalation — Phase 2
May 23, 2026 Clinical update
NT219 — Phase 2
May 23, 2026 Clinical update
NT219 — Phase 2
Aug 5, 2025 Patent grant
SGLTS/DPP4 inhibitor and application thereof
Sep 12, 2023 Patent grant
Bioactive concentrates and uses thereof

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is PURPLE BIOTECH?

Purple Biotech is a biotech organization headquartered in REHOVOT, L3, USA. It trades on NYSE under ticker PPBT. Primary therapeutic focus areas include Head and Neck Cancer, Solid Tumor, Solid Tumor, Adult. NovaPharmaNews links 3 clinical program(s), 1 drug profile(s), and 3 pat
Is PURPLE BIOTECH publicly traded?

Yes. PURPLE BIOTECH is listed with ticker PPBT on NYSE per SEC EDGAR records linked on this profile.
What drugs does PURPLE BIOTECH develop or market?

We link 4 drug profile(s) where PURPLE BIOTECH is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/purple-biotech-ltd#company-drugs.
What are the latest developments for PURPLE BIOTECH?

In the last 12 months our linked public records show 3 trial program update(s) and 1 US patent grant(s) tied to this profile.
What therapeutic areas does PURPLE BIOTECH focus on?

PURPLE BIOTECH focuses on Head and Neck Cancer, Solid Tumor, Solid Tumor, Adult based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Oncology

Others